hp inc buy pt solid result guidanc driven on-going pc out-performance continu option
valu print rais pt analyst nehal chokshi full summari
inc buy pt anoth strong quarter eaa highlight difficulti replic
technolog rais pt analyst nehal chokshi full summari
vmware inc hold pt rais guidanc given strong juli result remain cautiou mid-
term rais pt maintain hold rate analyst nehal chokshi full summari
brainstorm cell inc bcli buy pt safeti board green light nurown phase continu
corpor event call maxim salesperson inform
futur fit nutrit confer host vendetti nyc thur
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
inc cover klee ndr nyc ceo steve picket wed sept
inc cover klee ndr dalla brendan sullivan thur sept
agilysi inc cover klee ndr nyc ceo ramesh srinivasan cfo toni pritchett thur sept
agilysi inc cover klee ndr boston ceo ramesh srinivasan cfo toni pritchett fri sept
profir energi inc pfie cover jang ndr toronto ceo brenton hatch cfo ryan oviatt tue
safeti board green light nurown phase continu
brainstorm announc independ data safeti monitor board
dsmb complet interim safeti analysi pivot trial
nurown amyotroph later sclerosi al evalu first
patient safeti clear trial continu plan
move closer halfway mark late august trial enrol
al patient current activ enrol expect reach
januari complet
nurown studi al studi evalu impact
nurown cell al function rate scale score alsfrs-r week
first three dose far mani activ patient receiv
first two intrathec dose complet third expect data
announc earli potenti later depend speed
enrol
conclus far good dsmb safeti analysi clear trial
move unchang posit brainstorm next event updat
trial enrol also watch potenti expans
cns-base diseas recal nurown autolog non-
genet modifi cell cultur super secret neuron
growth factor multipl indic may benefit type
cell therapi view
nurown phase pivot trial studi six site on-lin us
activ enrolling/tr patient trial evalu three dose nurown
cell due brainstorm cryopreserv platform made use singl
harvest dose week follow-up seven month first dose
month announc trial enrol patient
current activ mani complet two three dose
alreadi complet three trial reach enrol januari
complet enrol mid-year
drug develop landscap al nurown clinic advanc outsid
support care al patient essenti therapeut option
radicava approv may multipl therapi includ gene therapi
develop vm biopharma us arm virom nr
develop modul growth factor serum level promot
angiogenesi improv surviv neuron nr
appli antisens platform mrna silenc prevent format mutat
play role certain inherit form al licens biogen
 nr al- pharma privat develop target monoclon
antibodi target misfold protein clinic develop begin
compani phase ab scienc ab pa nr brainstorm
reduc patient declin improv qol treatment studi
click full note
rais guidanc given strong juli result
remain cautiou mid-term rais pt maintain
octob quarter licens revenu guidanc beat consensu
guidanc rais across board
rais price target accord rais
guidanc maintain hold rate see period beat rais
come close benefit channel taper better
report juli quarter revenu y/i q/q
guidanc licens revenu y/i q/q
guidanc note q/q increas licens revenu line
averag past two year season perform
five-year q/q averag growth inclin believ above-
guidanc licens revenu larg result conserv guidanc strong
y/i growth result prior four quarter season out-performance larg due
revenu synergi associ leverag privat channel overal
bill increas y/i q/q primarili driven comput licens
book growth acceler y/i mid-singl digit overal
book growth driven continu hyper-growth vsan y/i in-lin
y/i apr acceler nsx growth y/i
y/i apr non-gaap ep y/i guidanc
cfo y/i well consensu estim
octob quarter licens revenu guidanc beat consensu
guidanc rais across board octob quarter revenu guidanc
y/i flat q/q licens revenu guidanc
y/i q/q guidanc paramet rais across board
includ total revenu rais y/i prior guid
licens revenu guidanc rais y/
prior guid om guidanc rais
ep rais y/i prior guid
guidanc rais y/i prior guid
oct licens revenu guidanc q/q well oct season
perform averag q/q note
consensu estim
rais price target accord rais guidanc
maintain hold rate see period beat rais come
close benefit channel taper better posit
long-term channel synergi realiz pace
reach initi indic octob continu
believ period beat rais come close rather
guidanc conserv also maintain long-term expect
 nr domin software-defin datacent market due
ownership best-in-cloud enterpris cloud comput asset azur well
strong on-premis infrastructur softwar offer expect bring
renew pressur core comput portion busi expect
mid-single-digit growth follow jan end especi expect
strike new partnership neutral improv channel
rais price target base
fcf-per-share estim vs prior fcf-per-share base period
increas net cash-per-share continu appli multipl
click full note
solid result guidanc driven on-going pc
out-performance continu option valu
print rais pt
juli quarter result driven on-going pc share gain
head guidanc octob
continu eye massiv option valu print
rais price target form index pt basi
juli quarter result driven on-going pc share gain report jul
revenu y/i y/i constant currenc
consensu estim non-gaap ep y/
q/q slightli ahead consensu estim
high end guidanc rel consensu person system
group psg oper profit beat consensu estim
psg revenu beat y/i consist y/i growth unit
out-performance rel idc estim industri unit y/i
also rel consensu imag print group oper profit
line consensu estim despit om
miss consensu estim due revenu beat y/
manag mention om q/q y/i
april primarili due strong unit placement go-to-market invest
larg relat addit s-print busi also note suppli
revenu y/i constant currenc normal s-print
revenu assum contribut estim jan april
flat y/ also note commerci print asp y/i vs
apr jan larg due acquisit samsung
printer busi refer s-print acceler y/i asp declin
like reflect manag decis aggress lower cost core
commerci placement note trend consist manag
expect normal suppli revenu trend flat y/i
forese futur also note oper profit out-performance larg
attribut strong pc out-performance unit y/i outpac idc estim
industri unit y/i
secur analyst meet octob manag provid in-
line non-gaap ep guidanc oct rang
consensu estim rais prior ep guidanc
prior guidanc compar prior consensu estim
manag also reiter prior guidanc least
y/i still rais jan guid manag provid
guidanc upcom octob nyc howev see
risk guidanc current consensu estim given
risk nand flash dram compon price face margin cycl
pc also come potenti creat margin compress
psg current level vs past five-year averag
latest propens continu invest keep om near vs
long-term guidanc aggress placement initi low-margin
printer continu invest go-to-market brand need
continu invest drive initi print well graphic
reduc om leav
psg om result overal corpor om estim go
thu ep
continu eye massiv option valu print upgrad share
buy may perform signific due dilig assess
viabil qs print roadmap led us conclud
well-thought-out cost-per-part reduct roadmap least period
compani hit initi mileston cost-per-part reduct
confid hpq assert year materi
inflect print observ regard opportun size believ
pois gener increment oper profit per year
next year vs current oper profit similar estim
gener increment gross profit iphon
rel base gross profit stock price increas
math behind increment oper profit vs current
overal oper profit includ machineri capit intens rate
manufactur industri market share similar hpq printer market
share oper margin similar asml engin moor law
rais price target form index pt basi
reiter buy rate continu util multipl use
compani coverag adjust lower growth natur
index forward price target basi ep estim
ep estim price target
increas
click full note
anoth strong quarter eaa highlight difficulti
replic technolog rais pt
jul licens revenu beat consensu highlight quarter
eaa sign view
oct revenu guidanc slightli consensu revenu guidanc
rais estim rais dcf-base price target
continu view secular buy
jul licens revenu beat consensu highlight quarter
eaa sign view jul revenu
y/i consensu estim guidanc
larg driven licens revenu y/i
consensu servic revenu y/i in-lin consensu
estim top-lin beat impress especi within context
softwar book cloud term increas
vs prior plan howev believ
true highlight quarter consolid engag across multipl
busi unit depart across rang siem much larger
opportun oper manag given amzn propens build vs buy
intern need henc origin impetu behind creation aw amzn
constant threat mani particip ecosystem well vers capabl
multipl differ big data technolog util schema read architectur
believ enter enterprise-wis adopt agreement eaa testifi
difficulti competitor replic technolog base built
review extens initi
oct revenu guidanc slightli consensu revenu guidanc
revenu midpoint guidanc y/i consensu estim
om guid vs consensu manag
rais revenu guidanc y/i prior guid
consensu estim also note previou guidanc
maintain om vs
rais estim rais dcf-base price target
continu view secular buy leav key
product input unchang includ termin period product metric
howev increas guidanc modestli better expect
spend juli quarter increas estim key
input waterfal revenu project product project
result modestli increas price target
termin period estim correspond assum
share siem market share much larger op management
app dev deliveri hypergrowth compani util dcf framework
mechan across compani specif make sure defer revenu
unchang termin period continu appli multipl
also continu view best big data invest amongst peer
given prior analysi indic best-in-class sale product
analysi initi report suggest unparallel big data
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
